Health CostsSee more about Health Costs
- state & global data
- view as grid
- view as list
The Kaiser Family Foundation, in partnership with the Peterson Center on Healthcare, today announced a new online hub dedicated to monitoring and assessing the performance of the U.S. health system. The Peterson-Kaiser Health System Tracker provides comprehensive data on how the system is performing on critical quality and cost measures,…
The Peterson Center on Healthcare and the Kaiser Family Foundation have partnered to monitor how well the U.S. healthcare system is performing in terms of quality and cost. The Peterson-Kaiser Health System Tracker is an online hub providing comprehensive data on how the system is performing on critical quality and cost…
In his latest column for The Wall Street Journal’s Think Tank, Drew Altman discusses this week’s Centers for Medicare and Medicaid Services report on health spending and assesses the current effort to control health-care costs.
With the approval of new specialty drugs, such as the Hepatitis C treatments Sovaldi and Harvoni, states are mindful that the cost the Medicaid prescription drug benefit could increase. To achieve savings, and improve management and health outcomes, it is important to understand which drugs are most frequently prescribed and which drive spending. Using state drug utilization data provided through the Medicaid Drug Rebate Program, as well as an industry drug database, this issue brief examines trends in prescriptions and spending before rebates, and places findings in the context of policy discussion.